Insider Purchases: Inside the Buy
Tag: Funanc1al Investing
Insiders Think Marvell Is a Wonder at Current Price; Should You Emulate the CEO, CFO, and Presidents and Buy MRVL?
Insiders, buybacks, and AI growth — oh my! Marvell Technology’s execs just bought millions in stock. With a $5B buyback, should you marvel too?
CEO Bought Shares of Vertex Pharmaceuticals (VRTX) A Bit Higher Back in August: Great Biotech At A Fair Price. Wait For Additional Pull-Back?
Vertex is more than cystic fibrosis drugs. With gene editing, pain relief, and even a potential T1D cure, the CEO’s insider buy raises one question: buy now or wait for additional pullback?
Bill Ackman's Pershing Square Still Owns Shares; A Director Bought Much Higher: Should You Go Long Chipotle (CMG) Or Just Eat the Burritos?
Chipotle Mexican Grill (CMG) stock has been cut in half from its highs, but institutions still love it and Bill Ackman still owns a big stake. Should you wrap CMG in your portfolio—or just stick to wrapping burritos?
Executive Chairman Adds To His Already Huge Stake in Ryan Specialty Holdings. Should You Follow His Lead?
Executive Chairman Patrick Ryan just added $14M to his already massive stake in Ryan Specialty Holdings. With strong revenue growth and heavy institutional backing, is this insurance play worth your portfolio — or is it still too pricey?
Insiders Pile Into Opendoor (OPEN) as New CEO Kasra Nejatian Bets on an ‘AI-First, Software-First’ Future — Should You Join the Cult Stock Rally?
Insiders are buying, retail traders are chanting, and Opendoor has a new AI-first CEO. From near-delisting to cult stock darling — is OPEN worth the hype?
Keurig Dr Pepper (KDP) Insiders Have Been Buying Shares. What’s Brewing?
Insiders are brewing confidence in Keurig Dr Pepper (KDP) with fresh stock buys, while institutions are holding heavy. With a mega coffee deal, spinoff plans, and steady results, is this stock about to perk up or get watered down?
Can Freshpet Make for a Fresh Buy: Insiders & Directors Think So
Freshpet’s stock has tumbled more than 70% from its highs, but insiders keep buying and Wall Street funds are all-in (119% ownership!). With revenue growing, profitability improving, and valuation looking much more reasonable, is this the turnaround treat investors have been waiting for? 🐾🍖
Salesforce (CRM): Insider Buys, AI Clouds, and Customer Armies — Should You Join the Ride?
Salesforce insiders are buying, AI is booming, and institutions are all-in. But is CRM stock really ready to rebound — or just blowing more cloud smoke? ☁️💸
Novocure (NVCR): From Electric Fields to Fighting Cancer — and Maybe Lifting Portfolios?
Novocure is zapping cancer cells with Tumor Treating Fields — and maybe giving investors a shock of opportunity. With insiders and institutions piling in, can NVCR rebound 94% from its crash? ⚡📈
Revisiting Why MSCI’s CEO Bought Shares Multiple Times Over the Past Year
MSCI’s CEO has spent over $11M buying shares in the past year. With institutions holding nearly 95% and margins above 60%, is MSCI worth the premium?